Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03995706 · ClinicalTrials.gov registry record · Early Phase 1
Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0
A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT03995706 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 26 participants.
The verdict
NCT03995706, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Single center, non-randomized, Phase 0 study. Sacituzumab Govitecan given preoperatively, followed by craniotomy with surgery or biopsy of brain tumors (GBM and metastatic brain tumors from Breast) and intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling.
Interventions
- DRUG Sacituzumab Govitecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-07-17 |
| Est. Completion | 2024-03-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03995706
The ClinicalTrials.gov registry entry for NCT03995706 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sacituzumab Govitecan is the first listed.
NCT03995706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03995706 about?
NCT03995706 is a clinical study titled "Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0". Single center, non-randomized, Phase 0 study. Sacituzumab Govitecan given preoperatively, followed by craniotomy with surgery or biopsy of brain tumors (GBM and metastatic brain tumors from Breast) and intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location...
What is the current status of trial NCT03995706?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2019-07-17. Estimated completion is 2024-03-20.
What interventions are being tested in trial NCT03995706?
The interventions under investigation include: Sacituzumab Govitecan (DRUG).
Who is sponsoring clinical trial NCT03995706?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.